Hunt Charles J
UK Stem Cell Bank, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK.
Methods Mol Biol. 2017;1590:41-77. doi: 10.1007/978-1-4939-6921-0_5.
Cryopreservation is the application of low temperatures to preserve the structural and functional integrity of cells and tissues. Conventional cooling protocols allow ice to form and solute concentrations to rise during the cryopreservation process. The damage caused by the rise in solute concentration can be mitigated by the use of compounds known as cryoprotectants. Such compounds protect cells from the consequences of slow cooling injury, allowing them to be cooled at cooling rates which avoid the lethal effects of intracellular ice. An alternative to conventional cooling is vitrification. Vitrification methods incorporate cryoprotectants at sufficiently high concentrations to prevent ice crystallization so that the system forms an amorphous glass thus avoiding the damaging effects caused by conventional slow cooling. However, vitrification too can impose damaging consequences on cells as the cryoprotectant concentrations required to vitrify cells at lower cooling rates are potentially, and often, harmful. While these concentrations can be lowered to nontoxic levels, if the cells are ultra-rapidly cooled, the resulting metastable system can lead to damage through devitrification and growth of ice during subsequent storage and rewarming if not appropriately handled.The commercial and clinical application of stem cells requires robust and reproducible cryopreservation protocols and appropriate long-term, low-temperature storage conditions to provide reliable master and working cell banks. Though current Good Manufacturing Practice (cGMP) compliant methods for the derivation and banking of clinical grade pluripotent stem cells exist and stem cell lines suitable for clinical applications are available, current cryopreservation protocols, whether for vitrification or conventional slow freezing, remain suboptimal. Apart from the resultant loss of valuable product that suboptimal cryopreservation engenders, there is a danger that such processes will impose a selective pressure on the cells selecting out a nonrepresentative, freeze-resistant subpopulation. Optimizing this process requires knowledge of the fundamental processes that occur during the freezing of cellular systems, the mechanisms of damage and methods for avoiding them. This chapter draws together the knowledge of cryopreservation gained in other systems with the current state-of-the-art for embryonic and induced pluripotent stem cell preservation in an attempt to provide the background for future attempts to optimize cryopreservation protocols.
冷冻保存是利用低温来维持细胞和组织的结构及功能完整性。传统的冷却方案会使冰在冷冻保存过程中形成,溶质浓度升高。溶质浓度升高所造成的损伤可通过使用称为冷冻保护剂的化合物来减轻。这类化合物可保护细胞免受缓慢冷却损伤的影响,使它们能够以避免细胞内结冰致死效应的冷却速率进行冷却。传统冷却的一种替代方法是玻璃化。玻璃化方法采用足够高浓度的冷冻保护剂以防止冰晶形成,从而使系统形成无定形玻璃,进而避免传统缓慢冷却所造成的损伤效应。然而,玻璃化也可能对细胞造成损伤,因为在较低冷却速率下使细胞玻璃化所需的冷冻保护剂浓度可能且通常是有害的。虽然这些浓度可降低至无毒水平,但如果细胞被超快速冷却,那么在后续储存和复温过程中,若处理不当,所形成的亚稳态系统可能会因玻璃化转变和冰的生长而导致损伤。干细胞的商业和临床应用需要稳健且可重复的冷冻保存方案以及合适的长期低温储存条件,以提供可靠的主细胞库和工作细胞库。尽管目前存在符合现行药品生产质量管理规范(cGMP)的临床级多能干细胞衍生和建库方法,且有适用于临床应用的干细胞系,但目前的冷冻保存方案,无论是玻璃化还是传统慢速冷冻,仍然不够理想。除了次优冷冻保存会导致有价值的产品损失外,还存在这样的风险,即此类过程会对细胞施加选择压力,筛选出具有非代表性的抗冻亚群。优化这一过程需要了解细胞系统冷冻过程中发生的基本过程、损伤机制以及避免损伤的方法。本章将其他系统中获得的冷冻保存知识与胚胎干细胞和诱导多能干细胞保存的当前技术水平相结合,试图为未来优化冷冻保存方案的尝试提供背景知识。